PCI Pharma Services Enters New Growth Phase with Strategic Investment
PCI Pharma Services Embarks on Next Growth Phase with Strategic Investment from Bain Capital, Kohlberg, and Mubadala PCI Pharma Services (PCI), a globally recognized contract development and manufacturing organization (CDMO)…
FDA Grants De Novo Nod to Reflow’s Spur Stent System
Reflow Medical Receives FDA De Novo Clearance for Spur Stent System, Marking a Breakthrough in Treatment of Below-the-Knee Peripheral Arterial Disease Reflow Medical, Inc., a pioneering company in the development…
CEL-SCI Closes $5.7M At-The-Market Stock Offering Under NYSE American Guidelines
CEL-SCI Secures $5.7 Million in At-the-Market Equity Offering to Advance Cancer Immunotherapy Program CEL-SCI Corporation (NYSE American: CVM), a clinical-stage biotechnology company dedicated to developing cancer immunotherapy treatments, has successfully…
Samsung Bioepis Whitepaper Calls for Policy Reforms to Boost Biosimilar Access in Europe
Samsung Bioepis Unveils European Policy Whitepaper to Bridge Gaps Hindering Biosimilar Access and Market Sustainability Samsung Bioepis Co., Ltd. has published a comprehensive whitepaper titled “Solving the Biosimilar Void in…
New Guideline Expands Access to Advanced Liver Ultrasound, Experts Say
New Guidelines Expand Access to Advanced Liver Imaging and Transplant Evaluations Using Contrast-Enhanced Ultrasound A new policy change is being hailed by medical experts as a transformative advancement in the…
HistoSonics Secures Coverage for Liver Tumor Therapy in 7M Highmark Members
HistoSonics Expands Access to Groundbreaking Non-Invasive Liver Tumor Treatment as Highmark Covers Histotripsy for 7 Million Members In a pivotal development for patients battling liver tumors, HistoSonics, the medical technology…
Acadia Unveils New Team and Pipeline, Eyes Biotech Powerhouse Status
Acadia Pharmaceuticals Unveils Ambitious Growth Strategy, Eyes $12 Billion Pipeline with Female-Led R&D Powerhouse More than three decades after its founding in 1993, Acadia Pharmaceuticals is embracing a bold new…
Takeda Reports Positive Phase 3 Results for Oveporexton in Narcolepsy Type 1
Takeda’s Oveporexton Achieves Landmark Phase 3 Success in Narcolepsy Type 1, Paving Way for First-in-Class Orexin Therapy Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) has announced a major milestone in its development…
ViiV Expands MPP Deal for Long-Acting HIV Treatment Access
ViiV Healthcare Broadens Voluntary Licensing Deal with MPP to Include Long-Acting Injectable HIV Treatment in Global Access Push GSK plc (LSE/NYSE: GSK) announced that its majority-owned subsidiary, ViiV Healthcare—a global…
Baxdrostat Meets All Endpoints in Phase III Hypertension Trial
Baxdrostat Achieves Positive Results in Phase III BaxHTN Trial, Demonstrating Significant Blood Pressure Reduction in Patients with Uncontrolled or Resistant Hypertension AstraZeneca has announced promising top-line results from its pivotal…
WHO Sets Up Collaborative Networks for Pathogen Genomics Surveillance
WHO’s International Pathogen Surveillance Network Launches Communities of Practice to Advance Genomic Surveillance The World Health Organization’s (WHO) Hub for Pandemic and Epidemic Intelligence has taken a major step forward…
Burundi Declared Free of Health as a Public Health Threat
Burundi Eliminates Trachoma as a Public Health Problem, Marking Major Milestone in Disease Control The World Health Organization (WHO) has officially validated that Burundi has eliminated trachoma as a public…